Finance

Lists
Why is NBTX down 3,10%?
Dive Deeper
NBTX:NASDAQ
Nanobiotix SA - ADR
22,94 USD
-3,10%
(-0,74) 1D
12-окт., 14:25:06 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBTX...
Open
23,72 USD
High
23,81 USD
Low
22,82 USD
Mkt. cap
1,17 млд
Avg. vol.
141,86 миң
Volume
137,84 миң
52-wk high
57,00 USD
52-wk low
14,78 USD
EPS
-1,22 USD
Beta
0,74
Shares outstanding
50,83 млн
No. of employees
98
Open
23,72 USD
High
23,81 USD
Low
22,82 USD
Mkt. cap
1,17 млд
Avg. vol.
141,86 миң
Volume
137,84 миң
52-wk high
57,00 USD
52-wk low
14,78 USD
EPS
-1,22 USD
Beta
0,74
Shares outstanding
50,83 млн
No. of employees
98
News stories
From web sources and news partners
Profile
Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts. Wikipedia
About Nanobiotix SA - ADR
CEOLaurent Levy
Employees98
Founded2003
Headquarters-
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to NBTX in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NBTX in the last 3 months.
Highest
Current 22,94 USD
64,00 USD (+178,93%)
Average
47,00 USD (+104,84%)
Lowest
30,00 USD (+30,75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Jeng
Guggenheim
Buy
Maintained
64,00 USD
+178,9%
09/25/2026
David Dai
UBS
Hold
Maintained
30,00 USD
+30,7%
09/25/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
09/25/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
36,00 USD
+56,9%
05/05/2026
Jonathan Chang
Leerink Partners
Buy
Maintained
37,00 USD
+61,3%
04/01/2026
Unknown Analyst
Guggenheim
Buy
Maintained
26,00 USD
+13,3%
02/05/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
2,98 млн
2,98 млн
2,78 млн
2,78 млн
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4,29 млн
4,29 млн
6,36 млн
6,36 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,53 млн
4,53 млн
5,38 млн
5,38 млн
Operating expense
8,83 млн
8,83 млн
11,74 млн
11,74 млн
Total operating expenses
8,83 млн
8,83 млн
11,74 млн
11,74 млн
Operating income
-5,85 млн
-5,85 млн
-8,96 млн
-8,96 млн
Other non operating income
-8,50 миң
-8,50 миң
-1,00 миң
-1,00 миң
EBT including unusual items
-9,29 млн
-9,29 млн
-17,14 млн
-17,14 млн
EBT excluding unusual items
-8,57 млн
-8,57 млн
-16,56 млн
-16,56 млн
Income tax expense
-1,50 миң
-1,50 миң
8,00 миң
8,00 миң
Effective tax rate
0,02%
0,02%
-0,05%
-0,05%
Other operating expenses
-
-
-
-
Net income
-9,29 млн
-9,29 млн
-17,14 млн
-17,14 млн
Net profit margin
-311,97%
-311,97%
-617,69%
-617,69%
Earnings per share
-
-
-
-
Interest and investment income
193,50 миң
193,50 миң
338,50 миң
338,50 миң
Interest expense
-3,08 млн
-3,08 млн
-7,28 млн
-7,28 млн
Net interest expenses
-2,88 млн
-2,88 млн
-6,94 млн
-6,94 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,79 млн
-5,79 млн
-8,84 млн
-8,84 млн
Gain or loss from assets sale
76,50 миң
76,50 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору